Page last updated: 2024-11-04

rofecoxib and Obesity

rofecoxib has been researched along with Obesity in 4 studies

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models."7.74Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008)
"The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity."7.74Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008)
"The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models."3.74Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008)
"The effect of rofecoxib (Vioxx), a cyclooxygenase (COX)-2 inhibitor, on adipose tissue development was studied in a murine model of diet-induced obesity."3.74Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. ( Gallacher, DJ; Lijnen, HR; Lu, HR; Van Hoef, B, 2008)
"Rofecoxib treatment decreased urinary PGF2alpha and 8-isoprostane levels in obese Zucker rats."1.32Rofecoxib decreases renal injury in obese Zucker rats. ( Dey, A; Imig, JD; Kaesemeyer, WH; Maric, C; Pollock, JS; Stewart, J; Zaharis, CZ, 2004)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nagai, N1
Hoylaerts, MF1
Gallacher, DJ2
Lu, HR2
Lijnen, HR3
Van Hoef, B1
Dey, A1
Maric, C1
Kaesemeyer, WH1
Zaharis, CZ1
Stewart, J1
Pollock, JS1
Imig, JD1

Other Studies

4 other studies available for rofecoxib and Obesity

ArticleYear
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
    Thrombosis research, 2008, Volume: 122, Issue:5

    Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Femoral Artery; Jugular Veins; Lactone

2008
Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:2

    Topics: Adipose Tissue; Animals; Blood Glucose; Cyclooxygenase 2 Inhibitors; Dietary Fats; Disease Models, A

2008
Effect of Vioxx on adipose tissue development in mice with genetically determined obesity.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:5

    Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease

2008
Rofecoxib decreases renal injury in obese Zucker rats.
    Clinical science (London, England : 1979), 2004, Volume: 107, Issue:6

    Topics: Animals; Chemokines; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cytoc

2004